Purpose: The purpose of this study was to assess the influence of positron emission tomographyecomputed tomography (PET-CT) results on patient management from a single Canadian oncology center during its first 2 years of operation. Methods: A total of 3,779 consecutive patients, 18 years of age and older, who were referred for PET-CT imaging at the British Columbia Cancer Agency between , 3,779 consecutive fluoro-2-deoxyglucose PET-CT examinations were performed in patients aged 18 years or older. A total of 3,429 referring-physician surveys (90.7%) were returned. The results of the PET-CT study resulted in a change in treatment decision in 49.8% of the studies and resulted in improved decision making in 83.2% of the studies. Conclusion: This series demonstrated that the results from PET-CT studies performed at a single Canadian oncology center during the first 2 years of its operation altered patient management in 50% of cases and resulted in improved decision making in the majority of cases.
Introduction
The Canadian Cancer Society and Statistics Canada estimated that 171,000 new cancer cases (excluding 75,100 nonmelanoma skin cancers) and 75,300 deaths from cancer will occur in Canada in 2009 [1] .
Positron emission tomography (PET) is a nuclear medicine imaging technology that allows noninvasive assessment of physiological and biochemical processes within the body. In oncology, PET provides information about the biochemical or functional status of tissue, which is important, because biochemical changes within tumours typically occur before anatomic changes.
More recently, a combined PETecomputed tomography (CT) scanner, with its shared mechanical components and designs, provides an optimum platform to fuse anatomic images from CT and functional or biochemical images from PET. Details of PET-CT scanner instrumentation and a flow chart of the typical PET-CT operation were reviewed by Alessio et al [2] . A combined PET-CT scanner provides both functional and anatomic information and has been incorporated into the diagnosis, staging, assessment of treatment response, and assessment of residual disease in a variety of cancer types.
To date the most widely used positron-emitting radiopharmaceutical in oncology has been fluoro-2-deoxyglucose (FDG) labeled with fluorine-18. FDG is a glucose analog, and the mechanism of cellular uptake and initial phosphorylation is similar to that of glucose. However, once FDG is phosphorylated to FDG-6-phosphate, it is not metabolized further and becomes trapped within the cell and consequently can be imaged by using PET. The degree of FDG accumulation within the cell, as measured by PET, is proportional to glucose uptake and metabolic activity of the tissue examined. Cells that have undergone malignant transformation tend to be hypermetabolic and demonstrate increased FDG transport and metabolism because of accelerated cell proliferation and increased hexokinase activity. Other positron-emitting radiopharmaceuticals, such as labeled amino acids, DNA precursors, tumour receptors, and cytostatic drugs, have also been developed for potential application in oncologic PET imaging [3e7]. Because many tumours contain heterogeneous cell populations, it is likely that multiple positronemitting radiopharmaceuticals may be necessary to adequately evaluate the diversity of tumours confronted in oncology.
The clinical use of PET scans is routine in the United States, many European countries, Australia, and Japan. In the United States, Medicare reimburses for PET scans for the diagnosis, staging, and restaging of selected common cancers [8] . In addition, reimbursement for most cancers can also be obtained provided that data are submitted to a National Oncologic PET Data Registry [9e11].
Although there are regional differences on the availability of PET within Canada, as of November 2007, there were 22 centers that perform publicly funded oncologic PET scans in 7 Canadian provinces [12] . Because of shorter acquisition times, the ability to provide a scaled attenuation correction map, and improved anatomic localization, PET-CT has now replaced dedicated PET for the systems currently being manufactured and installed. The first PET-CT scanner was installed in Canada in 2002. British Columbia has one publicly funded PET-CT scanner, which began clinical operations in July 2005. The purpose of this study was to assess the influence of PET-CT results on patient management from a single Canadian oncology center during the first 2 years of operation.
Patients and Methods
Consecutive patients, 18 years of age and older, who were referred for FDG PET-CT imaging at the British Columbia Cancer Agency (BCCA) between July 1, 2005 and June 30, 2007, were included in this analysis. Indications for performing PET-CT studies at the BCCA were approved by provincial tumours groups and can be found at http://www.bccancer.bc. ca/PPI/PET/indications.htm. Results were tabulated from a standard questionnaire, which was given to all referring physicians after the competition of their patient's PET-CT study. Referring physicians were asked to complete and return the questionnaire within 1 week after completion of their patient's PET-CT study. Physicians who did not complete the questionnaire were contacted by telephone 1e2 weeks after the examination and provided a reminder. Studies were performed under a clinical trial agreement with Health Canada, and informed consent was obtained from all patients.
A total of 4,003 PET-CT studies were performed at the BCCA from July 1, 2005 to June 30, 2007. Among these studies, 3,779 scans were performed in patients 18 years of age and older, and are included in this report. Patient preparation, image acquisition, and processing parameters were performed in accordance with the Society of Nuclear Medicine procedure guidelines [13, 14] . Precautions were taken to ensure that female patients were not breast feeding or pregnant. Patients were instructed to not consume any food or liquid (except water) for 6 hours before the study. Patient were also instructed to avoid chewing gum or strenuous exercise for 24 hours before the study. Blood glucometer measurement was performed before FDG administration.
With the patient resting comfortably, a weight-adjusted amount of FDG, which ranged from 300 to 550 MBq, was administered through a well-established intravenous line. The uptake phase from injection to imaging was between 45 and 90 minutes. All patients were imaged in the 3-dimensioal mode by using a CPS Biograph 16-slice Hi-Rez PET-CT (Siemens, Hoffman Estate, IL). The majority of the patients were scanned from the skull base to mid thigh with the arms abducted. Patients with head and neck cancers underwent an additional 2 bed position image of the head and neck, with the arms adducted. Whole body imaging (top of head to feet) was performed on selected patients with melanoma. For whole body plus head and neck PET acquisitions, patients were imaged for 3e4 minutes per bed position. For patients being evaluated with primary central nervous system (CNS) lesions, a dedicated single bed position 15-minute image of the brain was obtained.
For the CT portion of the study image acquisition, volumetric, noncontrast, 120 kVp, maximum 80 milliampere-second (mAs) (with ''CARE Dose'' tube current modulation) scans were acquired from the base of the brain to the mid thigh during tidal expiration. Maximum tube current was increased to 100 mAs for head and neck acquisitions. The table feed was 18 mm/ rotation, and slice thickness was 3 mm. PET data were acquired after the CT study, and both PET and CT data, standard CT, and iterative PET reconstructions were applied.
Attenuation corrected PET emission, noncorrected PET emission, and low mAs; noncontrast CT images were available for review by 3 experienced nuclear medicine physicians. Clinical reports were typically issued within 1e2 days after the completion of the study. Within 2 weeks of receiving the clinical report, the referring physicians were asked to complete a post-test questionnaire, which addressed the indication for performing the PET study and the impact of the study on the clinical care of the patients. (Figure 1 ). Patients with solitary pulmonary nodules and proven or suspected lung cancers were the most common type of referral and accounted for 1,371 of the studies performed in the first 2 years (36.3%). Other referral indications are tabulated in Table 1 .
Results

Between
British Columbia is geographically divided into 5 different health authorities ( Figure 2) [15] . The BCCA is a population-based cancer-control organization that provided cancer-related care for patients throughout the province. The relative distribution of the adult population within the health authorities and the percentage of patients referred from PET-CT study within each region were similar, which reflected a uniform usage of a provincial resource ( Table 2) .
A total of 3,429 referring physician surveys were returned (90.7%). The referring physicians' stated reasons for ordering the PET-CT are included in Figure 3 . The most frequent reason for ordering a PET-CT study was tumour staging, followed by evaluation of recurrent disease. The value of the PET-CT study and the influence of the results on the referring physician's patient management are presented in Table 3 . The results of the PET-CT study resulted in a change in treatment decision in 49.8% of the studies and improved decision making in 83.2% of the studies.
Discussion
PET-CT is a noninvasive imaging technique that measures the distribution and concentration of radiopharmaceuticals within the body. PET-CT scanners have become more widely available within Canada. In the 5 years between 2002 and 2007, the number of PET-CT scanners in Canada increased to 18 scanners [16] . Although improvements have been made, the number of PET scanners in Canada is fewer then other countries. For example, it has been estimated that, in the United States, there are approximately 5 PET scanners per million people [17, 18] . In a recent European study, it was estimated that the prevalence of PET scanners within a developed country should be approximately 1 per million [19] .
As shown in Table 2 , the location of patient referrals for PET-CT studies in both the first and the second year of operation closely paralleled the population within the health authority regions. This equitable assess to PET-CT within the province is not surprising given that the BCCA is a population-based cancer-control organization that serves the entire province.
FDG PET imaging in the oncologic patient was shown to be useful and cost effective in many tumour types [20e26]. In the first 2 years of operation at the BCCA, the most frequent indications for ordering a PET study was for staging, evaluation of recurrent disease, diagnosis, and monitoring response to treatment; PET studies were used most often in patients with lung cancer, gastrointestinal cancer (primarily colon and esophageal carcinoma), lymphoma, and head and neck cancers.
In the absence of prospective randomized outcome data; evidence that a diagnostic test alters patient management and results in improved decision making are important markers of the intrinsic value of a test. This current study confirms that the information derived from a PET-CT scan resulted in a change in an individual patient's treatment plan in 50% of the cases and resulted in improved decision-making ability in 83% of cases. Theses results are similar to results from the National Oncologic PET, which was initiated in May 2006 with the goal to collect data for cancers not currently covered by the Center for Medicare and Medicaid services. The National Oncologic PET Registry study evaluated nearly 23,000 patients and found that PET results were associated with a change in patient management in 36.5% of cases [10] . In a smaller consecutive series from a smaller communitybased study, Tucker et al [27] demonstrated that PET scanning changed patient management in 45% of studies and resulted in improved decision-making ability in 89% of studies.
Although the results of this study confirm that PET-CT was important in the management and evaluation of oncology patients, this study has several limitations. Although this is a consecutive series, this study is a retrospective review of a registry and, therefore, is subject to patient selection bias based on clinical need. For example, a subset of patients being evaluated presented as diagnostic dilemmas, and, therefore, it should not be too surprising that, in a proportion of these cases, the results of additional tests led to improved decision making. This patient selection bias would be less for patient referred for staging of disease, which was the most common reason for referral. Physicians were not required to complete a pretest questionnaire, which would have provided information on the referring physicians' management plans if PETs were not available. It is possible that the referring physicians may have had an a priori bias that the PET-CT results would change patient management, which may result in an overestimation of the magnitude of the benefit of the PET-CT study. Another limitation was that, although many cases were discussed and reviewed at tumour conferences, this study made no attempt to systematically obtain histopathologic follow-up to confirm PET scan results.
A final limitation of this study was that we failed to incorporate whether the physician's intention to change patient management was actually carried out and whether the resultant change in patient management had a positive impact on patient outcome. The inference that a resultant change in patient management is a positive benefit may be false. A PET-CT scan result, which appropriately does not alter patient management, would be more beneficial than results that inappropriately changed patient management. However, if there were a significant number of cases in which the PET-CT scan results inappropriately altered patient management, then one would not expect that 83% of studies would lead to improved decision making.
In conclusion, evidence that demonstrates that a diagnostic test alters patient management and results in improved decision making for the patient is the foundation of any newly introduced test. In this population-based series, we confirmed that the results from FDG PET-CT studies both altered patient management in 50% of cases and improved decision making in 83% of cases. The information provided to clinicians should result in better stage-specific and patientspecific therapies, which should translate into better patient outcomes. Further research is required to link the changes in patient management and improvement in decision making, with improved outcome and cost-effectiveness. Table 3 The effect of positron emission tomographyecomputed tomography (PET-CT) on patient management for the first 2 years (N ¼ 3429)
Question
Yes 
